Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognosis and Patient-Reported Outcomes of Combined Local Treatments (Surgery and Radiotherapy or Radiotherapy Alone) With Tislelizumab and Chemotherapy in Initial Stage III-N3 Non-Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm, Phase II Trial

NCT06908733 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.

NCT NCT06908733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognosis and Patient-Reported Outcomes of Combined Local Treatments (Surgery and Radiotherapy or Radiotherapy Alone) With Tislelizumab and Chemotherapy in Initial Stage III-N3 Non-Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm, Phase II Trial
Lead sponsor
Liaoning Cancer Hospital & Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
December 30, 2029
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (stage iii)